Featuring an interview with Dr Alexander E Drilon, including the following topics:

• Overview of targetable biomarkers in lung cancer (0:00)
• Biomarker testing for genomic alterations in lung cancer (5:24)
• Overview of ROS1 alterations in lung cancer (13:44)
• Efficacy data with ROS1 inhibitors for lung cancer (17:02)
• Safety data with ROS1 inhibitors for lung cancer (21:15)
• Case: A woman in her early 50s with a history of non-small cell lung cancer (NSCLC) undergoes biomarker testing to reveal a ROS1 fusion (28:56)
• Case: A man in his late teens diagnosed with de novo advanced NSCLC with a ROS1 alteration achieves a dramatic response to therapy (46:16)
• Case: A woman in her early 60s with a history of ROS1-altered NSCLC receives several ROS1 inhibitors (50:52)

NCPD information and select publications

Featuring perspectives from Mr Michael Lai, Dr Scott T Tagawa, Ms Stacy E Walker and Dr Evan Y Yu, moderated by Dr Tagawa, including the following topics:

• Introduction (0:00)
• Overview of Prostate Cancer (3:00)
• Hormonal Therapy for Nonmetastatic and Metastatic Hormone-Sensitive Prostate Cancer (HSPC) (6:12)
• Potential Role of Capivasertib in Metastatic HSPC (27:22)
• Current and Potential Future Role of PARP Inhibitors in Metastatic PC (46:39)
• Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic PC (1:09:14)

CME information and select publications

Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:

• Introduction (0:00)
• Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)
• Practical Considerations with Oral SERDs (15:42)
• Potential Role of Combination Approaches with Oral SERDs (26:31)
• Gastrointestinal Adverse Events Documented with Oral SERDs (38:17)
• Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:51)
• Other Class-Effect Toxicities Associated with Oral SERDs (1:00:53)
• Emerging Utility of Adjuvant Oral SERDs (1:10:16)
• Unique Toxicities Associated with 1 or More Oral SERDs (1:19:17)

CME information and select publications